This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
EMEA Growth & Product Launches to Support Boston Scientific Stock
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The Zacks Analyst Blog Highlights Walmart, Toyota Motor, Boston Scientific and Autoscope
by Zacks Equity Research
Walmart, Toyota Motor, Boston Scientific and Autoscope are included in this Analyst Blog.
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic
by Zacks Equity Research
Abbott Laboratories, Boston Scientific and Medtronic are included in this Analyst Blog.
Top Stock Reports for Walmart, Toyota Motor & Boston Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Toyota Motor Corp. (TM) and Boston Scientific Corp. (BSX), as well as a micro-cap stock Autoscope Technologies Corp. (AATC).
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
by Urmimala Biswas
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now
by Zacks Equity Research
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
Boston Scientific (BSX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 11.94% and 2.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $95.12, marking a -0.14% move from the previous day.
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
by Urmimala Biswas
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
by Zacks Equity Research
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Reasons to Hold TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
PAHC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI